Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency

Documenti analoghi

• SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
  di: Beck-Peccoz, Paolo, et al.
  Pubblicazione: (2019)
• Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
  di: Beck-Peccoz, Paolo, et al.
  Pubblicazione: (2020)
• Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment
  di: Pfäffle, Roland, et al.
  Pubblicazione: (2013)
• No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
  di: Beck-Peccoz, Paolo, et al.
  Pubblicazione: (2019)
• Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study
  di: Ferone, D., et al.
  Pubblicazione: (2017)